Skip to main content
. 2020 Oct 21;21(20):7802. doi: 10.3390/ijms21207802

Figure 4.

Figure 4

Intracellular Reactive Oxygen Species (ROS) and Malondialdeyde (MDA) quantification in MCF-7 cells (A,D) and MDA-MB-231 (B,E) cells treated with ipilimumab mAb in the presence of hPBMCs under different condition (high glucose; low glucose; high glucose + empagliflozin at 50 nm; shifting from a high glucose to low glucose). Untreated or treated cells with an unrelated control IgG (control) were used as negative controls; (C,F) Intracellular Reactive Oxygen Species (ROS) and Malondialdeyde (MDA) quantification in AC-16 cells, treated with ipilimumab mAb for 24 h, in the presence of hPBMCs under different conditions (high glucose; low glucose; high glucose + empagliflozin at 500 nM; shifting from a high glucose to low glucose). Untreated or treated cells with an unrelated control IgG (control) were used as negative controls. Error bars depict means ± SD (n = 3). Statistical analysis was performed using paired t-test. *** p < 0.001. ** p < 0.01. * p < 0.05.